Literature DB >> 11404517

Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.

S M Arpadi1, P A Cuff, M Horlick, J Wang, D P Kotler.   

Abstract

Alterations in regional fat, often associated with abnormalities in lipid and insulin metabolism, have been reported in HIV-infected adults. To determine whether similar abnormalities occur in children with HIV, patterns of change in regional body fat distribution were determined by dual energy x-ray absorptiometry in 28 prepubertal HIV-infected children. Eight (29%) children experienced lipodystrophy (LD), defined as extremity lipoatrophy together with trunk fat accumulation. Despite a mean body weight increase of 2.9 +/- 2.4 kg, children with LD experienced a mean loss of total fat in contrast to children without LD who increased total fat (-0.151 +/- 0.324 versus 0.981 +/- 1.041 kg; p <.01). Children with LD had significantly higher levels of HIV RNA and lower CD4 count and percentage at baseline. LD was associated with use of protease inhibitors or stavudine, (odds ratio [OR], 7.0, 95% confidence interval [CI], 1.1-45.2, p =.04; OR, 9.0, 95% CI, 1.4-59.8, p =.03, respectively). This observational study suggests that during a time in childhood when accumulation of extremity and trunk fat is expected, some HIV-infected children experience changes in fat distribution that are similar to HIV-associated LD reported in adults. Studies to determine whether HIV-infected children with changes in regional fat also experience increases in "atherogenic" lipids and insulin resistance as described in adults with HIV-associated LD are warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404517     DOI: 10.1097/00126334-200105010-00005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  27 in total

1.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

2.  Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

Authors:  C J Chantry; J S Cervia; M D Hughes; C Alvero; J Hodge; P Borum; J Moye
Journal:  HIV Med       Date:  2010-03-21       Impact factor: 3.180

3.  Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

Authors:  Luminita Ene; Tessa Goetghebuer; Marc Hainaut; Alexandra Peltier; Véronique Toppet; Jack Levy
Journal:  Eur J Pediatr       Date:  2006-07-29       Impact factor: 3.183

Review 4.  Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.

Authors:  Roy J Kim; Richard M Rutstein
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

5.  Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

Authors:  Ana María Sánchez Torres; Raquel Munoz Muniz; Rosario Madero; Clementina Borque; María Jesús García-Miguel; María Isabel De José Gómez
Journal:  Eur J Pediatr       Date:  2005-01-14       Impact factor: 3.183

Review 6.  Cardiovascular complications in children with HIV infection.

Authors:  Amy Sims; Colleen Hadigan
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

7.  Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood.

Authors:  David Dimock; Vijaya Thomas; Anna Cushing; Julia B Purdy; Carol Worrell; Jeffrey B Kopp; Rohan Hazra; Colleen Hadigan
Journal:  Metabolism       Date:  2010-10-13       Impact factor: 8.694

8.  Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus.

Authors:  Kunjal Patel; Jiajia Wang; Denise L Jacobson; Steven E Lipshultz; David C Landy; Mitchell E Geffner; Linda A Dimeglio; George R Seage; Paige L Williams; Russell B Van Dyke; George K Siberry; William T Shearer; Luciana Young; Gwendolyn B Scott; James D Wilkinson; Stacy D Fisher; Thomas J Starc; Tracie L Miller
Journal:  Circulation       Date:  2013-12-23       Impact factor: 29.690

9.  Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1.

Authors:  Tracie L Miller; E John Orav; Steven E Lipshultz; Kristopher L Arheart; Christopher Duggan; Geoffrey A Weinberg; Lori Bechard; Lauren Furuta; Jeanne Nicchitta; Sherwood L Gorbach; Abby Shevitz
Journal:  J Pediatr       Date:  2008-06-09       Impact factor: 4.406

10.  Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.

Authors:  J Jao; W Yu; K Patel; T L Miller; B Karalius; M E Geffner; L A DiMeglio; A Mirza; J S Chen; M Silio; E J McFarland; R B Van Dyke; D Jacobson
Journal:  HIV Med       Date:  2017-11-21       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.